Oppenheimer analyst Jay Olson raised the firm’s price target on Revolution Medicines (RVMD) to $60 from $55 and keeps an Outperform rating on the shares after the company provided clinical updates on ‘6236 and ‘9805 in PDAC at the triple meeting and hosted an investor event. Oppenheimer is “delighted” the updated ‘6236 Phase 1 data further improved with first reported mOS data strengthening the treatment paradigm-shifting potential of ‘6236 in 2L+ PDAC. The firm is also encouraged by the FIH data of ‘9805 in PDAC, showing encouraging signs of clinical activity and favorable safety profile that surpass expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines presents initial data from RMC-9805 study
- Revolution Medicines data validates RMC-6236’s anti-tumor activity, says Wedbush
- Revolution Medicines presents data from RMC-6236 Monotherapy Study
- Revolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment
- Revolution Medicines price target raised to $60 from $54 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com